Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16468424 | 0.87 | BRD4 (0.46) | BRD4BRD9 | |
| SCHEMBL20726642 | 0.82 | BRD4 (0.66) | BRD4BRD9 | |
| SCHEMBL16486285 | 0.82 | BRD4 (0.49) | BRD4BRD9 | |
| SCHEMBL16486199 | 0.79 | BRD4 (0.46) | BRD4BRD9 | |
| SCHEMBL19869661 | 0.79 | BRD4 (0.75) | BRD4BRD9 | |
| SCHEMBL15228321 | 0.78 | TPMT (0.47) | BRD4BRD9 | |
| SCHEMBL21383990 | 0.78 | LMNA (0.41) | BRD4BRD9 | |
| SCHEMBL2260637 | 0.78 | TTR (0.45) | — | |
| SCHEMBL480184 | 0.78 | TTR (0.45) | BRD4BRD9 | |
| SCHEMBL3163591 | 0.77 | CREBBP (0.44) | BRD4BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138525-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-21 | — | — | US | claimed |
| CN-1684954-A | N-substituted-2-oxodihydropyridine derivative | BANYU PHARMA CO LTD (JP) | 2005-10-19 | — | — | CN | claimed |
| EP-1546133-A2 | N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | claimed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | claimed |
| WO-2004031175-A2 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | WO | claimed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | claimed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| US-20210038602-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| WO-2020162471-A1 | PYRIDONE DERIVATIVE | マルホ株式会社 | 2020-08-13 | — | — | WO | disclosed |
| EP-3033335-B1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-15 | — | — | EP | disclosed |
| WO-2019145410-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-7138525-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| CN-1684954-A | N-substituted-2-oxodihydropyridine derivative | BANYU PHARMA CO LTD (JP) | 2005-10-19 | — | — | CN | disclosed |
| EP-1546133-A2 | N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-6869966-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | disclosed |
| WO-2004031175-A2 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | WO | disclosed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038602-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BRD4, MCL1, BET1 | BRD4 1/4885BRD9 13/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | BRD4 4391/4885BRD9 3332/4885 |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | NPY1R, NPY2R, NPY4R | BRD4 227/4885BRD9 1040/4885 |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | GPR119, NPY4R, NPY1R | BRD4 178/4885BRD9 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.